The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Blood-based biomarker strategy for assessing physiological age when treating myeloma
Ashley Rosko, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses the importance of biomarkers of aging for improving treatment decisions and minimizing toxicity in multiple myeloma (MM). Dr Rosko highlights that blood-based assays offer a robust method to assess patients’ physiological age, which may be more informative than traditional measures of chronological age. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
